Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab
Park, R. J.; Parikh, M.; Pappas, L.; Sade-Feldman, M.; Kulkarni, A. S.; Bi, L.; LaSalle, T. J.; Galway, A.; Kuhlman, C.; Blaszkowsky, L. S.; Meyerhardt, J. A.; Enzinger, P. C.; Biller, L.; Allen, J. N.; Kagey, M. H.; Baum, J.; Sirard, C.; Duda, D. G.; Zhu, A. X.; Abrams, T. A.; Hacohen, N.; Ting, D. T.; Mehta, A.; Goyal, L.
Show abstract
Biliary tract cancers demonstrate profound therapeutic resistance, and broadly effective therapies for refractory disease are lacking. We conducted a single-arm, second-line phase II trial combining DKN-01, a humanized monoclonal antibody targeting Dickkopf-1 (DKK-1), and nivolumab to treat patients with advanced biliary tract cancer (NCT04057365). No objective responses were seen. To identify mechanisms of treatment failure, we analyzed paired pre-treatment and on-treatment biopsies using scRNA-seq and constructed a detailed molecular classification of malignant and immune cells. We annotated five biliary tract cancer malignant cell states: classical, basal, mesenchymal, neural-like, and endothelial-like. Neural-like and endothelial-like states, which drive therapeutic resistance in other cancers, have not previously been described in BTC. Malignant cell states co-varied with distinct immune cell states, revealing diverse mechanisms of myeloid and T-cell mediated immune suppression, including M2 myeloid and terminally exhausted T cell programs that were induced by DKN-01/nivolumab. Here, we provide the first systematic classification of functionally annotated cell states in biliary tract cancer and provide new insight into resistance mechanisms to an immunotherapy combination that can inform the next generation of trials.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single-Cell RNA Sequencing Reveals the Effects of Chemotherapy on Human Pancreatic Adenocarcinoma and its Tumor Microenvironment 98%
- Spatial transcriptomics reveals ovarian cancer subclones with distinct tumour microenvironments 97%
- Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts 97%
Similar papers in this journal
- Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators 96%
- Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies 96%
- Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer 96%
Similar papers in this journal
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 97%
- Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies 97%
- Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy 96%
Similar papers in this journal
- Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing 96%
- Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment 95%
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors 95%
Similar papers in this journal
- Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases 96%
- TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes 96%
- Targeting DNA damage response and Replication Stress in Pancreatic Cancer 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.